hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) reported better-than-expected operating profits for Q4 2024 on Wednesday, thanks mainly to its GLP-1 drugs, including its popular weight loss therapy Wegovy, which added DKK 19.9B in sales, indicating over a twofold rise from a year-ago quarter.